Approved Ligands

MK-4827(Niraparib) is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM:with great activity in cancer cells with mutant BRCA-1 and BRCA-2:&gt:330-fold selective against PARP3,V-PARP and Tank1.

MK-4827(Niraparib) is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM:with great activity in cancer cells with mutant BRCA-1 and BRCA-2:&gt:330-fold selective against PARP3,V-PARP and Tank1.

MK-4827(Niraparib) is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM:with great activity in cancer cells with mutant BRCA-1 and BRCA-2:&gt:330-fold selective against PARP3,V-PARP and Tank1.

MK-4827(Niraparib) is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM:with great activity in cancer cells with mutant BRCA-1 and BRCA-2:&gt:330-fold selective against PARP3,V-PARP and Tank1.

MK-4827(Niraparib) is a selective inhibitor of PARP1/PARP2 with IC50 of 3.8 nM/2.1 nM:with great activity in cancer cells with mutant BRCA-1 and BRCA-2:&gt:330-fold selective against PARP3,V-PARP and Tank1.

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31

MLN2238 inhibits the chymotrypsin-like proteolytic (β5) site of the 20S proteasome with IC50 and Ki of 3.4 nM and 0.93 nM in cell-free assays, respectively, also inhibits the caspase-like (β1) and trypsin-like (β2) proteolytic sites, with IC50 of 31

Moexipril is a potent inhibitor to the angiotensin converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Moexipril in addition, has cardioprotective effects mediated through a combination of angiotensin II inhibition and

Moexipril is a potent inhibitor to the angiotensin converting enzyme, blocking the conversion of angiotensin I to angiotensin II. Moexipril in addition, has cardioprotective effects mediated through a combination of angiotensin II inhibition and